Interpretation of Urine Drug Testing in Pain Patients

被引：39

作者：

Pesce, Amadeo ^{[1
]}

West, Cameron ^{[1
]}

City, Kathy Egan ^{[1
]}

Strickland, Jennifer ^{[1
]}

机构：

[1] Millennium Res Inst, San Diego, CA 92127 USA

来源：

PAIN MEDICINE | 2012年 / 13卷 / 07期

关键词：

Pain Medication; Urine Drug Testing; Drug Metabolism; Patient Compliance; Alcohol Use; TANDEM MASS-SPECTROMETRY; CHRONIC NONCANCER PAIN; CHRONIC NONMALIGNANT PAIN; CHRONIC OPIOID THERAPY; DIRECT ETHANOL METABOLITE; MEDICALLY ILL PATIENTS; ETHYL GLUCURONIDE; PRIMARY-CARE; ORAL FLUID; SUBSTANCE USE;

D O I：

10.1111/j.1526-4637.2012.01350.x

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Background. Traditionally, urine drug screens have only been concerned with positive or negative results. Those results provide physicians treating patients for pain with chronic opioid therapy with information about medication compliance, use of nonprescribed medications, and use of illicit drugs. However, the analysis of urine for drugs offers additional information that, when compiled and accurately interpreted, may also be of great value to these doctors. Purpose: The aim of this article was to discuss the interpretation of urine drug tests and their application to pain physician practices. Method. We utilized a selection of recent articles on urine drug screening applicable to the pain patient population. Results and Conclusions. The article provides pertinent information about interpretation of urine drug testing, which is separated into six categories: which drugs and metabolites to test for; which analytical cutoffs to use; pain medication metabolism; identification of alcohol use; determination of patient compliance; and which patient groups to consider for more frequent testing.

引用

页码：868 / 885

页数：18

共 180 条

[1] Opioids and the treatment of chronic pain in a primary care sample [J].